Ranbaxy
May 28, 2012 at 11:26 | Source: Moneycontrol.com
May 28, 2012 at 09:56 | Source: CNBC-TV18
May 24, 2012 at 18:08 | Source: CNBC-TV18
May 23, 2012 at 15:00 | Source: CNBC-TV18
May 21, 2012 at 08:14 | Source: CNBC-TV18
News across the web »
May 28, 2012 at 11:11 | Source: Economic Times
May 28, 2012 at 04:51 | Source: Economic Times
May 26, 2012 at 22:27 | Source: Economic Times
May 26, 2012 at 08:01 | Source: FirstPost
May 25, 2012 at 17:42 | Source: Economic Times
Interact & exchange stock tips & market info »
This Blue chip available at the lowest PE, the correct price if you co...
about 1 hr 23 min 31 sec ago
Related News »
Ranbaxy Laboratories is going to launch Cipher Pharma's Absorica in US in October-December. The company will make USD 9 million milestone payment to Cipher for Absorica, reports CNBC-TV18. It touched an intraday high of Rs 537.00 and an intraday ...
May 28, 2012 at 05:59 | Source: MoneyControl.com
Tokyo, May 25 (PTI) Drug major Ranbaxy Laboratories today said it has hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India as part of a consent decree signed with the USFDA to revoke ban imposed by the ...
May 25, 2012 at 09:30 | Source: MSN India
May 9 (Reuters) - Ranbaxy Laboratories, India's top drugmaker by sales, reported a four-fold rise in quarterly net profit, helped by sales of its generic version of cholesterol drug Lipitor in its key U.S. market, sending its shares up more than ...
May 9, 2012 at 09:49 | Source: Reuters
Emkay Global Financial Services is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target price of Rs 559 in its May 09, 2012 research report. "Ranbaxy Laboratories, Q1CY12 Results - Revenues at Rs37bn (up 73% ...
May 15, 2012 at 09:13 | Source: MoneyControl.com
"We look forward to working closely with our partner, Ranbaxy Laboratories Inc., in preparation for the upcoming U.S. launch of the product through its dermatology sales force." "We are thrilled to make Absorica available as a valuable option ...
May 28, 2012 at 03:28 | Source: Yahoo Finance
- 'Reduce' rating is maintained on Ranbaxy with an unchanged target price of Rs.400 over one year. - Company's performance in 1QCY12 was weak except Lipitor. Sales of the generic 'Lipitor' in the range of USD 280 – 300 million was better than ...
May 25, 2012 at 15:13 | Source: equitybulls.com
GENERIC drug company Ranbaxy is giving chemists free supplies of its anti-cholesterol pill Trovas, rival to the nation's biggest-selling medicine Lipitor, in a move that means taxpayers are wasting about $410 million a year subsidising the drug.
May 27, 2012 at 13:09 | Source: The Australian
Law360, New York (May 23, 2012, 1:13 PM ET) -- A Johnson & Johnson unit on Monday hit two generic-drug makers with patent infringement suits in New Jersey federal court over their plans to make unbranded versions of the birth control pill Ortho Tri-Cyclen Lo.
May 23, 2012 at 17:10 | Source: site.law360.com
Ranbaxy reported a lower-than-expected performance for 1QCY2012. While the company's top line came in 26.1% below our expectation, the contraction in OPM was more than expected, which aided the adjusted net profit to come in 36.3% lower than our ...
May 16, 2012 at 18:30 | Source: equitybulls.com
Drug maker Ranbaxy Laboratories on Wednesday said its first-quarter consolidated net profit surged by 310 per cent to Rs 1,247 crore, from Rs 304 crore a year earlier, on strong growth in US sales. Net sales for the three months to March rose to Rs 3,695 ...
May 9, 2012 at 19:29 | Source: Business Standard